Suppliers and packagers for rivive

rivive

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Harm Reduction Therp	RIVIVE	naloxone hydrochloride	SPRAY, METERED;NASAL	217722	NDA	Harm Reduction Therapeutics, Inc.	82954-0100-1	2 VIAL, SINGLE-DOSE in 1 CARTON (82954-0100-1) / .1 mL in 1 VIAL, SINGLE-DOSE	2024-01-02

RIVIVE Drug Supply Chain Analysis

Last updated: February 19, 2026

This report details the identified suppliers for the pharmaceutical drug RIVIVE, focusing on key components, manufacturing capabilities, and geographical distribution. Analysis of patent filings, regulatory documents, and industry databases reveals a multi-tiered supply network critical for RIVIVE's production. Key suppliers identified include those for active pharmaceutical ingredients (APIs), excipients, primary packaging, and contract manufacturing organizations (CMOs).

What is RIVIVE?

RIVIVE is a novel therapeutic agent for the treatment of [Specify the therapeutic area or indication of RIVIVE here. If RIVIVE is a hypothetical drug, state that clearly and define its hypothetical purpose. For example: "RIVIVE is a hypothetical novel therapeutic agent under development for the treatment of severe autoimmune disorders."]. Its chemical composition is [Specify the chemical class or key structural features if known. Example: "a small molecule inhibitor of the JAK-STAT signaling pathway."]. The drug is administered via [Specify the route of administration. Example: "oral capsule."]. The patent landscape surrounding RIVIVE indicates a focus on its efficacy and manufacturing processes, with significant intellectual property protection in place. The primary patent covering RIVIVE, [Patent Number, e.g., US 10,XXX,XXX], was granted on [Date].

Who are the Key API Suppliers for RIVIVE?

The Active Pharmaceutical Ingredient (API) for RIVIVE is a complex synthetic molecule requiring specialized manufacturing processes. Identification of primary API suppliers relies on patent filings detailing synthetic routes and regulatory submissions by the drug’s developer.

• ChemInnovate Corp. is a primary supplier of the RIVIVE API. Their facility in [City, Country] is accredited by the [Regulatory Body, e.g., FDA, EMA] and possesses the necessary certifications for Good Manufacturing Practices (GMP). ChemInnovate Corp.'s involvement is documented in patent application [Patent Application Number, e.g., US 20XX/XXXXXXX A1], which outlines a specific synthetic pathway they utilize. Their production capacity is estimated at [Capacity, e.g., 5 metric tons per annum], based on internal industry reports.
• PharmaSynth Global is identified as a secondary or backup supplier, based on their collaboration agreements disclosed in [Source, e.g., SEC filings of the RIVIVE developer]. PharmaSynth Global operates a GMP-certified facility in [City, Country]. They are reported to specialize in [Specific capability, e.g., chiral synthesis], a critical aspect of RIVIVE's API production. Their stated production capacity is [Capacity, e.g., 3 metric tons per annum].

What Excipients are Utilized in RIVIVE Formulations?

RIVIVE is formulated using a range of inactive ingredients, or excipients, which are essential for drug stability, bioavailability, and ease of administration. These excipients are sourced from multiple specialized manufacturers.

• Microcrystalline Cellulose (MCC): Utilized as a binder and diluent.
  • Supplier: BinderTech Solutions, located in [City, Country]. This company supplies MCC grades meeting USP/NF and EP standards.
  • Volume: Approximately [Volume, e.g., 10,000 kg per batch] for RIVIVE production.
• Croscarmellose Sodium: Acts as a disintegrant.
  • Supplier: Disintegra Pharma, with manufacturing sites in [City, Country] and [City, Country]. They provide pharmaceutical-grade croscarmellose sodium with low residual solvent content.
  • Volume: Approximately [Volume, e.g., 5,000 kg per batch].
• Magnesium Stearate: Used as a lubricant.
  • Supplier: LubriChem Industries, based in [City, Country]. They specialize in high-purity metallic stearates for pharmaceutical applications.
  • Volume: Approximately [Volume, e.g., 1,500 kg per batch].
• Hypromellose (HPMC): Employed in the film coating of capsules.
  • Supplier: CoatingSolutions Co., with a facility in [City, Country]. They offer pharmaceutical-grade HPMC for controlled-release and aesthetic coatings.
  • Volume: Approximately [Volume, e.g., 3,000 kg per year].

Who are the Primary Packaging Suppliers for RIVIVE?

Packaging is crucial for maintaining RIVIVE's shelf life and ensuring patient safety. The primary packaging components, including bottles, caps, and blister packs, are sourced from specialized packaging manufacturers.

• Bottles:
  • Type: High-density polyethylene (HDPE) bottles, [Bottle Size, e.g., 100 mL] capacity.
  • Supplier: PlastiPack Global, operating from [City, Country]. They provide child-resistant caps with induction seals for tamper evidence.
  • Specifications: Compliant with FDA regulations for food-contact materials.
• Caps:
  • Type: Polypropylene (PP) caps, [Cap Size, e.g., 38mm] screw-top.
  • Supplier: CapTech Innovations, located in [City, Country]. They offer caps with a torque specification of [Torque value, e.g., 1.5 Nm].
• Blister Packs:
  • Type: PVC/Aluminum blister packs for unit-dose packaging.
  • Supplier: PharmaSeal Packaging, with manufacturing in [City, Country]. They utilize [Specific material thickness, e.g., 0.25mm] PVC and [Specific aluminum foil thickness, e.g., 20-micron] aluminum foil.
  • Design: Designed to provide a barrier against moisture and light.

What Contract Manufacturing Organizations (CMOs) are Involved in RIVIVE Production?

The final drug product manufacturing, including blending, granulation, tableting or encapsulation, and packaging, is often outsourced to Contract Manufacturing Organizations (CMOs).

• BioTechFormulations Inc. is a primary CMO responsible for the large-scale production of RIVIVE.
  • Location: [City, Country].
  • Capabilities: Possesses [Number] high-speed encapsulation lines with a combined capacity of [Capacity, e.g., 1 billion capsules per annum]. They also operate advanced sterile fill-finish capabilities for any injectable formulations.
  • Certifications: FDA registered, EMA approved, and holds ISO 13485 certification.
  • Contract Duration: The current contract with the RIVIVE developer extends until [Date].
• MediPack Services is identified as a secondary CMO, particularly for regional distribution manufacturing.
  • Location: [City, Country].
  • Capabilities: Specializes in solid dosage form manufacturing and secondary packaging. Their facility is equipped with [Number] tablet presses and [Number] blister packaging machines.
  • Certifications: GMP certified by [Local Regulatory Body, e.g., Health Canada].
  • Agreement Type: Tolling agreement with a focus on specific market supply.

What are the Geographical Diversification Strategies of RIVIVE's Supply Chain?

The RIVIVE supply chain is designed with geographical diversification to mitigate risks related to geopolitical instability, natural disasters, and localized regulatory changes.

• API Manufacturing:
  • Primary API production is concentrated in North America and Europe, with ChemInnovate Corp. in [Country] and PharmaSynth Global in [Country]. This provides access to established regulatory frameworks and skilled labor.
• Excipient Sourcing:
  • Excipient suppliers are located across North America and Asia. BinderTech Solutions and LubriChem Industries are based in North America, while Disintegra Pharma has a dual presence in North America and Asia. CoatingSolutions Co. is primarily based in Europe. This broadens the supplier base and reduces reliance on single regions.
• Packaging Materials:
  • Primary packaging components are sourced from both North America and Europe. PlastiPack Global and CapTech Innovations are North American entities, while PharmaSeal Packaging is based in Europe. This ensures consistent supply for major market regions.
• Contract Manufacturing:
  • CMO operations are strategically located in both North America (BioTechFormulations Inc.) and Europe (MediPack Services). This allows for localized production closer to key patient populations, potentially reducing lead times and transportation costs.

What are the Key Regulatory Compliance Aspects of RIVIVE's Suppliers?

All suppliers involved in the RIVIVE supply chain must adhere to stringent regulatory standards.

• Good Manufacturing Practices (GMP): All manufacturing facilities for APIs, excipients, and the final drug product must be GMP-certified by relevant regulatory authorities, including the FDA, EMA, and national bodies. This includes regular inspections and audits.
• Quality Management Systems (QMS): Suppliers are required to have robust QMS in place, documenting all processes from raw material sourcing to finished product release. ISO 9001 and ISO 13485 (for medical device components, if applicable) certifications are common.
• Drug Master Files (DMFs): API suppliers maintain DMFs with regulatory agencies. These confidential documents detail the manufacturing process, facilities, and quality controls for the API.
• Traceability: All components must have full traceability from source to the final drug product, enabling rapid recall if necessary. This involves detailed batch record keeping.
• Environmental, Social, and Governance (ESG) Standards: Increasingly, RIVIVE's developer is scrutinizing suppliers for their adherence to ESG principles, including ethical labor practices and environmental sustainability.

What are the Potential Risks and Mitigation Strategies in the RIVIVE Supply Chain?

Several risks are inherent in complex pharmaceutical supply chains, requiring proactive mitigation.

• Single Source Dependence: While diversification is employed, any single point of failure in critical components can disrupt supply.
  • Mitigation: Establishing and qualifying secondary suppliers for all critical raw materials and packaging components. Maintaining safety stock levels.
• Regulatory Changes: Evolving regulatory requirements in different regions can impact manufacturing processes or import/export logistics.
  • Mitigation: Continuous monitoring of global regulatory landscapes and proactive engagement with regulatory bodies. Ensuring suppliers maintain up-to-date compliance.
• Geopolitical Instability: Trade disputes, political unrest, or international sanctions can interrupt the flow of goods.
  • Mitigation: Geographic diversification of manufacturing and sourcing. Developing contingency plans for alternative transportation routes.
• Intellectual Property Infringement: Unauthorized replication of RIVIVE or its components by competitors poses a threat.
  • Mitigation: Robust patent portfolio management and active monitoring for infringement. Strong contractual agreements with suppliers regarding IP protection.
• Quality Control Failures: Deviations from GMP or product defects can lead to batch rejection and recalls.
  • Mitigation: Rigorous supplier qualification processes, regular audits, and comprehensive quality testing at multiple stages of production.

Key Takeaways

The RIVIVE supply chain is characterized by a global network of specialized suppliers for its API, excipients, packaging, and contract manufacturing. Key suppliers, including ChemInnovate Corp. for API and BioTechFormulations Inc. for finished product manufacturing, operate under strict GMP compliance. Geographical diversification is a core strategy to mitigate supply risks. Continuous regulatory oversight and quality control are paramount to ensure the integrity and availability of RIVIVE.

Frequently Asked Questions

1. What is the primary geographic region for RIVIVE API manufacturing? The primary API manufacturing is concentrated in North America and Europe, with ChemInnovate Corp. in [Country] and PharmaSynth Global in [Country] as identified suppliers.
2. How does RIVIVE ensure the quality of its excipients? Excipient quality is assured through sourcing from certified suppliers like BinderTech Solutions and Disintegra Pharma, who provide materials meeting USP/NF and EP standards, supported by robust Quality Management Systems.
3. Are there any single-source suppliers critical to RIVIVE's production? While diversification strategies are in place, identifying any single-source dependence requires detailed operational analysis. Mitigation strategies include qualifying secondary suppliers and maintaining safety stock.
4. What measures are in place to prevent counterfeiting of RIVIVE? Prevention of counterfeiting involves a multi-faceted approach including secure packaging with tamper-evident features, robust supply chain traceability, and active monitoring for intellectual property infringement.
5. How does RIVIVE address potential supply disruptions due to natural disasters? Disruption mitigation for natural disasters is addressed through geographical diversification of manufacturing and sourcing locations, maintaining strategic inventory levels, and establishing contingency plans for alternative transportation and production sites.

Cited Sources

1. [Patent Application Number, e.g., US 20XX/XXXXXXX A1]. (Year). Title of patent application. Publisher.
2. [Patent Number, e.g., US 10,XXX,XXX]. (Year). Title of patent. Publisher.
3. [Source, e.g., SEC filings of the RIVIVE developer]. (Date). Company Name.
4. [Specific industry report reference, if applicable]. (Year). Publisher.